Page last updated: 2024-12-11

verrucosidin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

verrucosidin: tremorgenic mycotoxin; structure given in first source; RN given refers to (1alpha,2alpha(1E(2S*,3R*),3E),4alpha,5alpha)-(+-)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6437365
CHEMBL ID512656
SCHEMBL ID846397
MeSH IDM0138871

Synonyms (9)

Synonym
verrucosidin
CHEMBL512656
4-methoxy-3,5-dimethyl-6-[(2r,3s)-2-methyl-3-[(2e,4e)-4-methyl-5-[(1s,2s,4r,5r)-2,4,5-trimethyl-3,6-dioxabicyclo[3.1.0]hexan-2-yl]penta-2,4-dien-2-yl]oxiran-2-yl]pyran-2-one
d-altritol, 2,5:3,4-dianhydro-1,6-dideoxy-2-c-((1e,3e)-4-((2s,3r)-3-(4-methoxy-3,5-dimethyl-2-oxo-2h-pyran-6-yl)-3-methyloxiranyl)-2-methyl-1,3-pentadienyl)-4-c-methyl-
88389-71-3
2h-pyran-2-one, 6-(3-(1,3-dimethyl-4-(2,4,5-trimethyl-3,6-dioxabicyclo(3.1.0)hex-2-yl)-1,3-butadienyl)-2-methyloxiranyl)-4-methoxy-3,5-dimethyl-, (1s-(1alpha,2alpha(1e(2s*,3r*),4alpha,5alpha)))-
SCHEMBL846397
Q15427942
DTXSID701045464

Research Excerpts

Overview

Verrucosidin is a tremorgenic mycotoxin responsible for neurological diseases. It has been detected in different dry-ripened foods as consequence of the growth of toxigenic molds.

ExcerptReferenceRelevance
"Verrucosidin, which is a tremorgenic mycotoxin responsible for neurological diseases, has been detected in different dry-ripened foods as consequence of the growth of toxigenic molds. "( Duplex real-time PCR method with internal amplification control for quantification of verrucosidin producing molds in dry-ripened foods.
Andrade, MJ; Córdoba, JJ; Rodríguez, A; Rodríguez, M; Werning, ML, 2012
)
2.04

Effects

ExcerptReferenceRelevance
"Verrucosidinol has a ring-opened ethylene oxide moiety in the polyene α-pyrone skeleton, and verrucosidinol acetate is its acetate derivative."( Verrucisidinol and verrucosidinol acetate, two pyrone-type polyketides isolated from a marine derived fungus, Penicillium aurantiogriseum.
Chen, C; Dai, H; Ren, B; Song, F; Sun, J; Wei, J; Yu, K; Zhang, L, 2010
)
1.41
"Verrucosidinol has a ring-opened ethylene oxide moiety in the polyene α-pyrone skeleton, and verrucosidinol acetate is its acetate derivative."( Verrucisidinol and verrucosidinol acetate, two pyrone-type polyketides isolated from a marine derived fungus, Penicillium aurantiogriseum.
Chen, C; Dai, H; Ren, B; Song, F; Sun, J; Wei, J; Yu, K; Zhang, L, 2010
)
1.41

Toxicity

ExcerptReferenceRelevance
" Verrucosidin appeared to have the highest toxic potential, testing positive in both assays."( Genotoxicity assessment of five tremorgenic mycotoxins (fumitremorgen B, paxilline, penitrem A, verruculogen, and verrucosidin) produced by molds isolated from fermented meats.
Fink-Gremmels, J; Nijmeijer, S; Sabater-Vilar, M, 2003
)
1.44
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID338666Toxicity in ip dosed mouse
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (7.14)18.7374
1990's0 (0.00)18.2507
2000's5 (35.71)29.6817
2010's6 (42.86)24.3611
2020's2 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.96

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.96 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index5.10 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.96)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (6.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (93.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]